Your account is not claimed yet. You can sign up with ORCID to claim your account.

Julie A Rytlewski (Julie Rytlewski)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 4

Top Venues

PloS one

Nature medicine

Blood cancer discovery

Juno Therapeutics

University of Texas at Austin (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Juno Therapeutics May 13o 2019

United States

Principal Scientist :: Informatics and Predictive Sciences

Education History

University of Texas at Austin Aug 25o 2008 - Dec 7o 2013

United States

PHD :: Biomedical Engineering

Publications

Juan José Lahuerta, Irene Manrique, Julie A Rytlewski, Timothy Campbell, Christian C Kazanecki, Nathan Martin, Larry D Anderson, Jesus G Berdeja, Sagar Lonial, Noopur S Raje, Yi Lin, Phillipe Moreau, Jesús San F Miguel, Nikhil C Munshi, Shari Kaiser
Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel. Blood cancer discovery (2023)
Sarah A Johnson, Spencer L Seale, Rachel M Gittelman, Julie A Rytlewski, Harlan S Robins, Paul A Fields
Impact of HLA type, age and chronic viral infection on peripheral T-cell receptor sharing between unrelated individuals. PloS one 16 (8) (2021)
Julie A Rytlewski, Shibing Deng, Tao Xie, Craig B Davis, Harlan Robins, Erik Yusko, Jadwiga Bienkowska
Model to improve specificity for identification of clinically-relevant expanded T cells in peripheral blood. PloS one 14 (3) (2019)
Timothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, Willy Hugo, Alexander H Lee, Tom B Davidson, Anthony C Wang, Benjamin M Ellingson, Julie A Rytlewski, Catherine M Sanders, Eric S Kawaguchi, Lin Du, Gang Li, William H Yong, Sarah C Gaffey, Adam L Cohen, Ingo K Mellinghoff, Eudocia Q Lee, David A Reardon, Barbara J O'Brien, Nicholas A Butowski, Phioanh L Nghiemphu, Jennifer L Clarke, Isabel C Arrillaga-Romany, Howard Colman, Thomas J Kaley, John F de Groot, Linda M Liau, Patrick Y Wen, Robert M Prins
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature medicine 25 (3) (2019)

Julie A Rytlewski.css-eqlu8i{font-size:small;padding-left:4px;} (Julie Rytlewski)

Publication Activity (10 Years)

Top Topics

Top Venues

Julie A Rytlewski (Julie Rytlewski)